Clinical and regulatory intelligence for Graves' Disease with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 2

Relevant assets

BHV-1300 →

IMVT-1402 →

Relevant companies

Biohaven Therapeutics →

Recent signals(2)

ClinicalJuly 23, 2026

Immunovant's IMVT-1402 Enters Phase 2b for Graves' Disease Treatment

Immunovant Sciences is conducting Phase 2b trial of IMVT-1402 for adults with Graves' disease unresponsive to antithyroid drugs.

ClinicalJune 30, 2026

Biohaven's BHV-1300 Trial for Graves' Disease Underway

Biohaven Therapeutics is conducting a trial to assess the efficacy and safety of BHV-1300 in adults with Graves' disease.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Endocrinology →

Graves' Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.